2nd Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$180,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Address concerns with Medicare Independent Payment Advisory Board (IPAB)

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Copyright/Patent/Trademark CPT

Address provisions in patent reform legislation (HR 1249/S 23) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 1249 (112th)

Health Issues HCR

Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 2182 (112th)

Taxation/Internal Revenue Code TAX

Support extension of the R&D tax credit. Support repeal of medical device tax. Support extension of Therapeutic Discovery Project program.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpilefunding and preparation; FDA Appropriations

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Support HR 1862, the Regenerative Medicine Promotion Act. Support NIH funding.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1862 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.